{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380580230613238018.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Takuya Kawahara"}],"foaf:familyName":[{"@value":"Kawahara"}],"foaf:givenName":[{"@value":"Takuya"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360580230613238016","@type":"Article","resourceType":"学術雑誌論文(journal article)","productIdentifier":[{"@type":"DOI","@value":"10.1016/j.breast.2022.10.017"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0960977622001825?httpAccept=text/xml"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0960977622001825?httpAccept=text/plain"},{"@type":"DOI","@value":"10.21203/rs.3.rs-1112686/v1"},{"@type":"PMID","@value":"36371994"}],"notation":[{"@value":"Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.breast.2022.10.017_gvFaisOEjMvagKumlPXMWpFNLD"},{"@type":"OPENAIRE","@value":"doi_dedup___::052908a824bed912320414613d9fd96d_gvFaisOEjMvagKumlPXMWpFNLD"}]}